Abstract: A polyisocyanate production system is provided that can stably produce chlorine from hydrogen chloride produced secondarily while reacting stably between carbonyl chloride and polyamine and can perform an effective treatment of the hydrochloric gas produced secondarily. A hydrochloric gas control unit 32 controls a flow-rate control valve 23 to keep constant an amount of hydrogen chloride supplied from a hydrogen chloride purifying tank 4 to a hydrogen chloride oxidation reactor 6 via a second hydrochloric-gas connection line 11 to be constant, and also controls a pressure control valve 22 based on an inner pressure of the hydrogen chloride purifying tank 4 input from a pressure sensor 25 to discharge the hydrochloric gas from the hydrogen chloride purifying tank 4 to the hydrogen chloride absorbing column 5 via a first hydrochloric-gas connection line 10, so as to keep an inner pressure of the hydrogen chloride purifying tank 4 to be constant.

Abstract: An autoclave comprises an enclosure 10 defining a chamber 12, steam supply means 20, 22 arranged to supply steam to the chamber, steam venting means 34, 40, 58, 60 arranged to vent steam from the chamber, and control means 100, 102 arranged to control operation of the autoclave. The control means comprises a first controller 100 and a second controller 102, each controller being arranged to define a respective set of conditions required for a change of state of the autoclave, to monitor a parameter of the autoclave and determine therefrom whether its respective conditions have been met, and the control means is arranged to allow the change of state only if both sets of conditions have been met.

Abstract: A fluid disinfection module (10) comprises a first housing (12) and a second housing (20) arranged in spaced-apart relationship to each other. The first housing (12) includes tubular support members (28) and (28a) extending laterally therefrom for respective slidable mateable engagement with corresponding tubular support members (30) and (30a) also laterally extending from second housing (20), to vary the lateral distance x between the first and second housings (12) and (20). A locking device maintains tubular support members (28,28a) and (30,30a) in fixed relationship with respect to each other. First housing (12), second housing (20), and corresponding tubular support members (28,28a) and (30,30a) define a framework for supporting one or more ultraviolet radiation sources (18) and (26) that are detachably mounted at one end thereof to housings (12) and (20), respectively.

Abstract: An insulation package for microwave synthesis of phosphors includes an insulator and a susceptor configuration. The insulator has a cavity defined therein, wherein the cavity is adapted to receive a phosphor starting material. The susceptor configuration is positioned within the cavity, wherein the insulator, the cavity, and the susceptor configuration are substantially symmetrically disposed in relation to an axis of rotation of the insulation package. In a first embodiment, the susceptor configuration includes a plurality of susceptor rods. In an alternative embodiment, the susceptor configuration includes an inner tube and an outer tube, wherein granular susceptors are encased between the inner tube and the outer tube.

Abstract: A catalytic purification device including a substrate permeable to exhaust gases, is optionally impregnated with catalytic materials, and is provided with an upstream face and an opposing downstream face; and an envelope containing the permeable substrate and defining an enclosure provided with an inlet line and an outlet line, between which the permeable substrate is arranged, the upstream face of the permeable substrate projecting along the extension of the inlet line, and the axis of the inlet line defining, with the upstream face (14A), an angle smaller than 20°. The envelope includes a deflector arranged at the outlet of the inlet line, the deflector being inclined towards the upstream face and used to orient the exhaust gases escaping from the inlet line towards the permeable substrate. The envelope also includes elements for creating turbulence in the flow along the upstream face.

Abstract: A catalytic converter assembly is provided that includes a metallic tubular member having a first end and a second end. A first substrate is disposed within the metallic tubular. A second substrate is disposed within the metallic tubular member. A spacer is axially positioned the between the first and second substrate that includes a cylindrical body with a first wall and a second wall formed substantially perpendicular to the cylindrical body. The first wall abuts an end of the first substrate for retaining the first substrate between the first end and the first wall for preventing movement. The second wall abuts an end of the second substrate for retaining the second substrate between the second end and the second wall for preventing movement.

Abstract: A liquid reducing agent container structure adapted for an exhaust emission purifying system that is capable of reductively purifying NOx in the exhaust gas using a liquid reducing agent, and provided with a configuration such that a lock (42, 60, 70) is detachably disposed on the outer face of an inlet port (34) disposed on a container body (24A) of a reducing agent container (24), and an engagement portion (36a, 50, 54, 56, 58) with which a locking member (42d, 60d, 70b) of the lock (42, 60, 70) can be engaged is disposed on the side of a cap member (36) which is configured to be screwed on the inlet port (34) to seal the inlet port (34), thereby engaging the locking member (42d, 60d, 70b) with the engagement portion (36a, 50, 54, 56, 58) with a locking operation by the lock (42, 60, 70) to block and prevent a rotation of the cap member (36).

Abstract: An improved reactor for an HF alkylation unit of the shell-and-tube heat exchanger type has an axial tube bundle to provide cooling for the reactor and a centrally-located axial sparger system for injecting and dispersing the hydrocarbon reactants into the flow path in the reactor. The sparger comprises an axially-extensive tube with outlet nozzles for the hydrocarbon reactants arranged around the tube, preferably with differing radial angles, at different locations along the length of the sparger.

Abstract: A parallel reactor system including a reactor and vessels in the reactor for holding reaction mixtures, and a cannula for introducing fluid reaction material into the vessels. A robot system is operable to insert the cannula into cannula passages in the reactor for delivery of reaction materials, including condensed gases, to respective vessels, and to withdraw the cannula from the cannula passages after delivery. Related methods are also disclosed.

Abstract: The present disclosure is directed to an apparatus and method for studying dissolution of a compact sample. The compact sample is typically a pharmaceutical drug sample. A flow-through apparatus includes a frame defining a flow-through channel, a removable insert having a drug sample, the insert positioned within the frame such that a fluid interacts with the sample when the fluid passes through the flow channel. The frame has an opening on the top side to allow a glass plate, typically a microscope cover slip to be positioned within the frame and allow viewing of the fluid flow and interaction with the drug sample. The hydrodynamics of the fluid flow are either known or computed. Thus, dissolution can be studied and observed in view of hydrodynamic characteristics. Typically, only a small amount of sample is necessary for a study. The flow-through apparatus is designed to fit on a microscopy stage and allow visual observation of the fluid/sample interaction.

Abstract: The present teachings are directed towards a thermolysis method of producing iron-containing nanoparticles by providing an iron-containing component, a colloid stabilizing component, and an amount of water. The iron-containing component, the colloid stabilizing component, and the amount of water form a mixture, which is then heated to a temperature sufficient to form iron-containing nanoparticles, which are then isolated from the mixture. Another method is also provided which involves a repetitive shell growth method of producing iron-containing nanoparticles by providing a first amount of an iron-containing component and a colloid stabilizing component; the iron-containing component and the colloid stabilizing component are then mixed and heated to a temperature sufficient to form iron-containing nanoparticles.

Abstract: A process for the recovery of nickel and cobalt from a nickeliferous oxidic ore by heap leaching, the process including the steps of a) forming the nickeliferous oxidic ore into one or more heaps; b) leaching the ore heap with a leach solution in a leach step wherein the leach solution includes an acid supplemented hypersaline water as the lixiviant, the hypersaline water having a total dissolved solids concentration greater than 30 g/l; and c) recovering the nickel and cobalt from the resultant heap leachate.

Abstract: A mercury removing device includes a gasification unit that converts a non-gaseous-mercury-chlorinating agent, which is non-gaseous at room temperature and normal pressure, into gaseous-mercury-chlorinating agent by heating the non-gaseous-mercury-chlorinating agent with heat of hot air generated by using the exhaust gas or hot air generated by using an air heater installed in a flue that conveys the exhaust gas. The gaseous-mercury-chlorinating agent produced in this manner is supplied to the exhaust gas in the flue.

Abstract: The present invention describes methods and systems for extracting, capturing, reducing, storing, sequestering, or disposing of carbon dioxide (CO2), particularly from the air. The CO2 extraction methods and systems involve the use of chemical processes. Methods are also described for extracting and/or capturing CO2 via exposing air containing carbon dioxide to a solution comprising a base—resulting in a basic solution which absorbs carbon dioxide and produces a carbonate solution. The solution is causticized and the temperature is increased to release carbon dioxide, followed by hydration of solid components to regenerate the base.

Abstract: Method and means for modifying gases or fumes fed through a filter (1), from its inlet side to its outlet side, submitted to an electric plasma having its maximum plasma density (d) at the filter's inlet side. The gases or fumes may comprise NOx, the filter being constituted by a catalytic material fit for modifying NOx. The filter also may be polluted with e.g. a soot deposit, precipitated on the filter's surface and/or within the filter's interior. The means may comprise a first electrode system (2) at the filter's inlet side and a second electrode system (3) at the filter's outlet side, connected to a high voltage (V1). Preferably the first electrode system comprises two or more groups of interlacing electrodes, each connected to a high voltage source (V1, V2, V3).

Abstract: Rare earth compositions comprising nanoparticles are described along with various nanotechnology applications of such nanoparticles. The compositions of the nanomaterials discussed may include scandium (Sc), yttrium (Y), lanthanum (La), cerium (Ce), praseodymium (Pr), neodymium (Nd), promethium (Pm), samarium (Sm), europium (Eu), gadolinium (Gd), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er), thulium (Tm), ytterbium (Yb), and lutetium (Lu).

Abstract: Disclosed herein are cerium doped, garnet phosphors emitting in the yellow region of the spectrum, and having the general formula (Y,A)3(Al,B)5(O,C)12:Ce3+, where A is Tb, Gd, Sm, La, Sr, Ba, Ca, and/or Mg, and substitutes for Y, B is Si, Ge, B, P, and/or Ga, and substitutes for Al, and C is F, Cl, N, and/or S, where C substitutes for O. Relative to a solid-state-reaction method, the instant co-precipitation methods provide a more homogeneous mixing environment to enhance the distribution of the Ce3+ activator in the YAG matrix. Such a uniform distribution has the benefit of an increased emission intensity. The primary particle size of the as-prepared phosphor is about 200 nm, with a narrow distribution.

Abstract: A process for fluorination of borohydride salts including providing a reaction medium comprising HF and a superacid. A borohydride salt compound is added to the reaction medium. The borohydride salt is reacted with the with the reaction medium under conditions to form a fluorinated borohydride salt. In addition, reactor vessels may be provided for reacting the HF, superacid additive and borohydride that are fabricated from materials resistant to superacid compositions.

Abstract: The present invention is for a porous silicon powder comprising silicon particles wherein the outermost layers of said particles are porous. The present invention is also directed to a method of making this porous silicon powder using a stain etch method. The present invention is also directed to a method of making silicon nanoparticles from the porous silicon powders using a process of ultrasonic agitation. The present invention also includes methods of processing these silicon nanoparticles for use in a variety of applications.

Abstract: A method for making ultra-fine carbon fibers and activated ultra-fine carbon fibers includes core-sheath melt-spinning to produce a core-sheath fiber including a sheath made of polyolefin and a carbon-containing polymer, and a core made of a polyolefin polymer. Under control of temperature, the core-sheath fiber is stabilized as a carbon-containing precursor fiber. The stabilized core-sheath fiber is carbonized in nitrogen at 600 to 1500 degrees Celsius and converted into ultra-fine carbon fibers with a diameter of 20 to 800 nm. Then, the ultra-fine carbon fibers are activated in carbon dioxide, steam, air or any combination thereof at 600 to 1500 degrees Celsius to form activated ultra-fine carbon fibers.

Abstract: It is an object to provide a method for producing stable alkaline metal oxide sols having a uniform particle size distribution. The method comprises the steps of: heating a metal compound at a temperature of 60° C. to 110° C. in an aqueous medium that contains a carbonate of quaternary ammonium; and carrying out hydrothermal processing at a temperature of 110° C. to 250° C. The carbonate of quaternary ammonium is (NR4)2CO3 or NR4HCO3 in which R represents a hydrocarbon group, or a mixture thereof. The metal compound is one, or two or more metal compounds selected from a group of compounds based on a metal having a valence that is bivalent, trivalent, or tetravalent.

Abstract: Disclosed herein are wall flow reactors that are suitable for the production of hydrogen gas from hydrocarbon and/or its derivative feed streams. The wall flow reactors are generally comprised a monolithic honeycomb substrate defining a plurality of cell channels bounded by porous channel walls that extend longitudinally from an upstream inlet end to a downstream outlet end; wherein a first portion of the plurality of cell channels are plugged at the downstream outlet end to form inlet cell channels and a second portion of the plurality of cell channels are plugged at the upstream inlet end to form outlet cell channels. A plurality of catalyst layers are positioned within at least a portion of the plurality of cell channels and comprise at least a first catalyst layer and a second catalyst layer. Also disclosed are methods for treating reactant feed streams.

Abstract: A quantity of solution sufficient to dissolve a pH controlling substance and/or substantially dissolve a surfactant without substantial excess solution is controlled under a set of time and temperature conditions to transform an inorganic material having long-range crystallinity to a mesostructure having long-range crystallinity. The method employs concentrated conditions that have a consistency similar to a thick slurry. The economic viability of scaling up such thick slurry methods is improved relative to prior more dilute methods of transforming an inorganic material to a mesostructure.

Abstract: This invention relates to a hybridoma cell line which is capable of producing the monoclonal antibody G250. Furthermore, the invention describes the method of employing such cell line for the production and manufacture of monoclonal antibody G250 as well as derivatives thereof such as chimeric and humanized G250 antibodies.

Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.

Abstract: The invention relates to the treatment and prevention of atherosclerosis and cardiovascular diseases associated with atherosclerosis. The invention further relates to methods of diagnosing atherosclerosis and cardiovascular diseases associated with atherosclerosis. In certain embodiments, the invention provides biological systems and methods for delivering a therapeutic agent or an imaging agent to atherosclerotic lesions such as vulnerable plaques.

Abstract: Conjugates of porphyrin, chlorophyll and bacteriochlorophyll photosensitizers with RGD-containing peptides or RGD peptidomimetics are provided that are useful for photodynamic therapy (PDT), particularly vascular-targeted PDT (VTP), of tumors and normeoplastic vascular diseases such as age-related macular degeneration, and for diagnosis of tumors by different techniques.

Abstract: A method of imaging apoptosis in vivo, using radiolabeled annexin, is described.

Abstract: The present invention is directed to compositions and methods of making and using compositions that are useful for treating cells or conditions caused or exacerbated by cell survival mechanisms of the body, particularly conditions exacerbated by cell survival mechanisms involving NF-KB. The compositions and methods of the present invention comprise a sensitizing agent or a chemopotentiating agent. In this regard, cobalamin drug conjugates and NO donors act as chemopotentiating agents. Nitrosylcobalamin is particularly useful as a sensitizing or chemopotentiating agent, and methods utilizing nitrosylcobalamin prior to, simultaneous with and subsequent to radiation or chemotherapy are described, as are compositions which first release a nitrosylcobalamin compound or biologically active analog thereof, and then release the chemotherapeutic agent. Nitrosylcobalamin itself is a chemotherapeutic, and when administered in conjunction with other anti-cancer agents or techniques, a synergistic effect is seen.

Abstract: It is intended to provide a radioactive tyrosine derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 represents a group selected from the group consisting of —11CH3, —11CH2CH3, —CH218F, and —CH2CH2CH218F.

Abstract: The present invention relates to Radiolabeled Arylsulfonyl Compounds and methods of use thereof as imaging agents for the COX-2 enzyme using positronemission tomograpy (PET). Methods of making the Radiolabeled Arylsulfonyl Compounds and pharmaceutical compositions comprising an effective amount of a Radiolabeled Arylsulfonyl Compound are also disclosed.

Abstract: The present invention relates to Radiolabeled Compounds and methods of use thereof for treating or preventing a psychiatric disorder in a subject, for stabilizing the mood of a subject having a mood disorder, or as imaging agents for a serotonin receptor. Compositions comprising an imaging-effective amount of a Radiolabeled Compound are also disclosed.

Abstract: Disclosed herein are peptides with domains that promote lipid efflux from cells and optionally possess at least one anti-inflammatory domain or a domain that stimulates LCAT activity. Provided herein are methods of using the peptides to treat or inhibit diseases including dyslipidemic disorders, stroke and myocardial infarction. Also provided are methods of detecting plaque in vessels using the labeled peptides of the present invention.

Abstract: A steroid ester compound of a terminally-fluorinated alkyl fatty acid, a steroid compound having bis(trifluoromethyl)phenyl group, a phosphatidylserine compound having a terminally-fluorinated alkyl group, a glyceride compound having bis(trifluoromethyl phenyl group, or a glyceride compound having a terminally-fluorinated alkyl group. A vascular lesion can be selectively imaged by using a contrast medium comprising a liposome containing said compound or a salt thereof.

Abstract: Methods and devices for administration of substances into the intradermal layer of skin for systemic absorption.

Abstract: The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds, and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C1-4 alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the ?7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission.

Abstract: Long-term treatment of conditions associated with neovasculature is effected by combining targeted acute antiangiogenic agent treatment with chronic treatment with an additional drug.

Abstract: Medical applications for an infrared emitting composite are provided. The infrared emitting composite includes an infrared emitting agent dispersed in a matrix material, where the composite emits light of a wavelength range substantially non-absorbent to animal fluid or tissue. A system and method for detecting an infrared emitting composite are also provided. Exemplary applications for an infrared emitting composite include medical devices and pharmaceutical compositions.

Abstract: The present invention discloses a fluorocarbon emulsion enhancement agent for HIFU treatment, which can increase acoustic energy deposition at the target location during HIFU treatment. The enhancement agent comprises a discontinuous phase comprising of a core material encapsulated by a membrane-forming material and a continuous phase comprised of aqueous medium; the discontinuous phase is uniformly dispersed in the continuous phase and the particle size of the discontinuous phase ranges from 0.1-2 ?m; the amount of the membrane-forming material in the enhancement agent is 0.1-100 g/L; the core material is comprised of a liquid that undergoes a liquid-gas phase transition at 38-100° C., and the amount of the core material in the enhancement agent is 5-200 ml/L. The fluorocarbon emulsion enhancement agent for HIFU treatment of the present invention can significantly change the acoustic environment of the target location and can increase acoustic energy deposition at the target location during HIFU treatment.

Abstract: The present invention discloses sulfonamide A-(Q)n—Ar—SChNHR which are CA IX-selective inhibitors, which selectively bind to the enzyme under hypoxic conditions and are able to reverse the tumor acidification mediated by the enzyme. These compounds are useful in anticancer therapies based on tumor-associated CA isozyme inhibition as well as for hypoxic tumor imaging.

Abstract: The present invention generally relates to agents and compositions having MRI and/or optical signals, and methods for their use in the determination of an analyte. In some cases, an optical, MRI, or other signal produced by the agent or composition may be affected by the presence of an analyte. Some embodiments of the present invention may provide agents or compositions which are cell permeable. Examples of analytes that may be determined by the present invention include zinc ions, calcium ions, and other biological analytes.

Abstract: The invention relates to an alcohol-free cosmetic or pharmaceutical foam carrier comprising water, a hydrophobic solvent, a foam adjuvant agent, a surface-active agent and a water gelling agent. The cosmetic or pharmaceutical foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil soluble pharmaceutical and cosmetic agents.

Abstract: The invention relates generally to a system and method for treating conditions responsive to nicotine therapy. More specifically, the invention relates to pulmonary administration of a nicotine containing formulation to effect smoking cessation.

Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of a selective cytokine inhibitory drug. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

Abstract: The present invention provides a foamable composition for administration to the skin, body surface, body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum. The foamable oil in water nano emulsion composition includes: (a) a nano oil globule system, comprising substantially of sub-micron oil globules; (b) about 0.1% to about 5% by weight of at least one stabilizing agent, selected from the group consisting of (i) a non-ionic surfactant, (ii) an ionic surfactant, and (iii) a polymeric agent; and (c) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition, water and optional ingredients are added to complete the total mass to 100%. Upon release from an aerosol container, the foamable composition forms and expanded foam suitable for topical administration.

Abstract: Pyran derivatives of general formula (I) wherein Y is a 5-, 6- or 7-membered ring, preferably a 5-membered ring, methyl or ethyl mono- or polysubstituted, and optionally unsaturated, and R1, R2, R3, R4 are, each independently, a hydrogen atom or a linear or branched C1-5 alkyl or C2-5 alkenyl group, and X is present or absent; when X is present, R5, R6, R7, R8, R9 are all present, and X is a hydrogen atom or an OZ group, wherein Z is a hydrogen atom or a R10 group or a C(O)R10 group; when X is absent, a double bond involving the carbon atom at the 4 position is present and R7, R8 and R9 are present, and one of R5 or R6 is present and the other one is absent, or R5, R6, and R7 are present, and one of R8 or R9 is present and the other one is absent, or R7 is a ?C(R11)(R12) group and R5, R6, R8, R9 are present; and when they are present, each of R5-R12 group is, independently, a hydrogen atom or a linear or branched C1-5 alkyl or C2-5 alkenyl group; and use of at least one pyran derivative of formula (I)

Abstract: Disclosed are oral care compositions and their use, comprising in an orally acceptable carrier: (a) from about 0.01 to about 10% by weight of an essentially water-insoluble zinc compound, and (b) from about 0.01% to about 10% by weight of a compound having C—O—P bonds selected from polyphosphorylated inositol compounds such as phytic acid, myo-inositol pentakis(dihydrogen phosphate); myo-inositol tetrakis(dihydrogen phosphate), myo-inositol trikis(dihydrogen phosphate), and an alkali metal, alkaline earth metal or ammonium salt thereof. The compositions are effective in preventing and controlling oral cavity conditions including plaque, calculus, caries, periodontal disease, mouth malodor and dental erosion and have acceptable aesthetics without the unpleasant astringent and metallic taste associated with the use of zinc.

Abstract: The present invention relates to the use of a compound Licochalone A (5-(1,1-Dimethylallyl)-4,4?-dihydroxy-2-methoxychalcone)) as well as Glycyrrhiza inflate Betal flavonoid extract, Glycyrrhiza glabra L. flavonoid extract, Glycyrrhiza kansuensis (Chang et Peng) flavonoid extract, a flavonoid extract of a mixture of two to three of the above licorices, or a mixture of two or three of the above licorice flavonoid extracts, which contains Licochalone A, in inhibiting primary oral pathogenic microorganisms and manufacturing oral care products for countering breath odor, preventing dental caries and reducing dental plaques, reducing gingivitis, tooth desensitizing, anti-calculus, and/or tooth whitening, and relates to oral pharmaceuticals and oral care products thereof.

Abstract: The present invention relates to a cosmetic composition comprising, in a cosmetically acceptable medium: a polymer resulting from the copolymerization: a) at least one monomer A chosen from esters resulting from the reaction of (meth)acrylic acid with a monoalcohol containing from 2 to 20 carbon atoms, b) at least one monomer B chosen from esters derived from the reaction of methacrylic acid with a monoalcohol containing from 1 to 10 carbon atoms, and c) at least one monomer C chosen from N-vinyllactams and derivatives thereof, and an organic solvent phase comprising at least one first organic solvent, the said phase being free of lower monoalcohol containing from 1 to 5 carbon atoms or of C3-C4 ketone, or containing them in a weight content, relative to the total weight of the composition, of less than or equal to 15%.

Abstract: The properties of 2-pyrrolidone-4-carboxylic substituted polysiloxanes can be dramatically altered by increasing the presence of the carboxylic-substituted pyrrolidone monomer of the polysiloxane, such that the amidopolysiloxane has an acid equivalent weight of about 3:00-3,000 daltons and a molecular weight average Mw of about 1,000-60,000 daltons resulting in enhanced detergent and water solubilities and the ability to form water-in-oil emulsions thereby providing usefulness across a broad range of formulations having enhanced electrolytic and silicone and/or hydrocarbon compatibility and cleansing properties.